Q4 2025 SeQuent Scientific Ltd Earnings Call Transcript
Key Points
- Sequent Scientific Ltd (BOM:512529) reported a strong revenue growth of 11.2% year-on-year for Q4 FY25, reaching INR4,017 million.
- The company's Formulation business showed a robust 22% year-on-year growth, contributing significantly to the overall revenue.
- Gross margins improved by 420 basis points year-on-year, reaching 50.3% in Q4 FY25.
- EBITDA pre-ESOP for the quarter grew by 38.7% year-on-year, with a margin expansion of 280 basis points.
- The company achieved a significant turnaround in profit after tax, improving from a loss last year to a profit of INR322 million for FY25.
- The tax rate for Sequent Scientific Ltd in Q4 FY25 was relatively high at 35-36%, impacting net profitability.
- Viyash Life Sciences, a subsidiary, experienced a 3% sequential decline in revenue, attributed to inventory buildup in the US.
- The company's cash conversion from EBITDA remains low, with cash getting stuck in receivables and higher inventory levels.
- The API business, while showing improvement, still faces challenges in achieving consistent growth and margin expansion.
- The company has not provided specific guidance for FY26, creating uncertainty about future performance expectations.
Ladies and gentlemen, good day, and welcome to SeQuent Scientific Limited Q4 FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
A very good morning to all of you, and thank you for joining us today for SeQuent Scientific's earnings conference call for the fourth quarter and full year ended financial year 2025. Today, we have with us Mr. Rajaram, MD and CEO of SeQuent Scientific; Dr. Hari Babu, Whole-Time Director and CEO, Viyash Life Sciences; Mr. Saurav, CFO, SeQuent Scientific; and Mr. Ramakant, CFO, Viyash Life Sciences, to share the highlights of the business and financials for the quarter.
I hope you've gone through our results release and the quarterly investor presentation, which have been uploaded on our website as well as the stock exchange website. The transcript of this call will be available in a week's time on the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
